Sep 29 2014
Curemark, a leading drug research and development company focused on the treatment of neurological and other diseases, is proud to announce that Dr. Joan Fallon, Founder and CEO, will receive Springboard Enterprises' Northstar Award, as recognition for her entrepreneurial leadership and achievements in autism research. Springboard Enterprises is a non-profit organization dedicated to accelerating high-growth women entrepreneurs' access to equity capital markets. Its 2014 Winners' Circle Dinner will take place at The Boathouse in Central Park in New York on October 21.
"Dr. Fallon is a visionary scientist who has dedicated her life to helping patients by tailoring treatments that address the root causes of their disorder. Her groundbreaking work and study of children with autism will lead to meaningful improvements in the lives of children with autism," said Amy Millman, President of Springboard Enterprises. "We are proud to present Dr. Fallon with the Northstar Award for exemplifying true entrepreneurialism in her unwavering commitment to making her dream of developing a treatment that will help children with autism a reality."
Curemark began with Dr. Fallon's research on the role of gastrointestinal/pancreatic secretory deficiencies in neurological disease. Critical insights from her clinical observations treating children led to the development of the company's lead product candidate, CM-AT, which has the potential to be a first-in-class treatment for autism and the first therapy to address the core symptoms of the disease.
"I am proud to be recognized by Springboard for this important award," stated Dr. Fallon. "Springboard is an important organization that is dedicated to raising industry support and capital for women-led, high-growth-potential entrepreneurial endeavors focused on the advancement of humanity through breakthrough innovation. I look forward to collaborating with Springboard in the future in any way that I can to enable more women to realize their dreams."